London, Canada - Viron Therapeutics' lead drug candidate, VT-111, has been selected as one of the top 10 most promising cardiovascular drugs in development, offering significant potential for strategic partnering. The selection was made by an independent committee assembled by Windhover Information, a leading provider of business information products and services to senior executives in the pharmaceutical, biotechnology, and medical device industries.